Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Northwest Biotherapeutics ( (NWBO) ) has provided an update.
On December 12, 2025, Northwest Biotherapeutics entered into a settlement agreement with lead plaintiff F. Glenn Schaeffer to resolve Delaware Chancery Court litigation over stock option awards granted to company management and directors in 2020. After roughly a year of negotiations and mediation, the deal provides that the company’s insurers will pay $2.25 million to the company, 17% of the disputed 2020 options will be cancelled, and all claims between the parties will be fully settled, while any court-approved attorneys’ fees, for which the plaintiff plans to seek up to $3.5 million, will be paid separately by insurers, with the overall settlement still subject to court approval at a hearing scheduled for March 16, 2026.
More about Northwest Biotherapeutics
Northwest Biotherapeutics operates in the biotechnology sector, focusing on the development of cancer immunotherapies and related biopharmaceutical products aimed at treating solid tumor cancers in global markets.
Average Trading Volume: 3,802,750
Technical Sentiment Signal: Hold
Current Market Cap: $440.6M
See more data about NWBO stock on TipRanks’ Stock Analysis page.